Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4012 participants.

Also called NCT01938248

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 4,012 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01938248
  • EudraCT 2014-001397-33
Other papers using this trial's data
  • Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation The New England journal of medicine, 2024-01-11 DOI, PubMed 37952132
  • Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial The Lancet. Neurology, 2025-02 DOI, PubMed 39862882
  • Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA Journal of the American College of Cardiology, 2024-07-23 DOI, PubMed 39019530
  • Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial JAMA cardiology, 2025-12-01 DOI, PubMed 41222953, PMC12613090 Not in the PMC Open Access subset.
  • Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial Circulation, 2024-11-26 DOI, PubMed 39229707 PubMed links an erratum for this paper. Erratum: PMID 39836762

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01938248. Randomized; quadruple masking; primary purpose prevention. Start 2015-05 (actual); primary completion 2023-10-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
Acronym
ARTESiA
Condition
Stroke
Intervention (Drug)
Apixaban
Intervention (Drug)
aspirin
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)
Collaborator
Pfizer (class: industry)
Collaborator
Medtronic (class: industry)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct01938248
Content hash
0f6b690d60fcd9461641bd2ab246cd486b9aa68d06f6bfa84fa8dfc034480dfe